ASCO 2024 | The potential role of luxdegalutamide, an oral PROTAC AR degrader, in mCRPC

Daniel Petrylak • 31 May 2024

ASCO 2024

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, discusses how luxdegalutamide, an oral PROTAC AR degrader that was assessed in a Phase I/II study (NCT05067140), can fit into the current treatment landscape for metastatic castration-resistant prostate cancer (mCRPC). As approximately a quarter of patients have ligand binding domain mutations, the novel PROTAC AR degrader will benefit patients who have progressed on androgen targeting drugs such as abiraterone and enzalutamide. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding – Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony – Celgene; sanofi